2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 624 / Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04950933 (ClinicalTrials.gov) | June 1, 2020 | 27/6/2021 | The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules | A Multi-center, Randomized, Double-blind, Positives Parallel Controlled, Phase ? Clinical Trial to Evaluate the Efficacy and Safety of Huollingshengji Granules in the Treatment of Amyotrophic Lateral Sclerosis (Spleen qi Deficiency, Kidney Yang Deficiency Syndrome) | Amyotrophic Lateral Sclerosis | Drug: Huolingshengji Granules;Drug: Riluzole tablet | Peking University Third Hospital | The Second Hospital of Hebei Medical University | Recruiting | 45 Years | 70 Years | All | 144 | Phase 2/Phase 3 | China |